Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)Retained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming (PHAR) Convertible Debt (2020 - 2025)

Historic Convertible Debt for Pharming (PHAR) over the last 6 years, with Q3 2025 value amounting to $93.1 million.

  • Pharming's Convertible Debt rose 112.81% to $93.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $93.1 million, marking a year-over-year increase of 112.81%. This contributed to the annual value of $78.2 million for FY2024, which is 4278.54% down from last year.
  • As of Q3 2025, Pharming's Convertible Debt stood at $93.1 million, which was up 112.81% from $91.3 million recorded in Q2 2025.
  • In the past 5 years, Pharming's Convertible Debt ranged from a high of $145.4 million in Q2 2021 and a low of $120005.0 during Q3 2022
  • Its 5-year average for Convertible Debt is $98.8 million, with a median of $128.2 million in 2022.
  • In the last 5 years, Pharming's Convertible Debt plummeted by 9991.49% in 2022 and then soared by 10800632.89% in 2023.
  • Quarter analysis of 5 years shows Pharming's Convertible Debt stood at $140303.5 in 2021, then skyrocketed by 93709.5% to $131.6 million in 2022, then rose by 3.78% to $136.6 million in 2023, then tumbled by 42.79% to $78.2 million in 2024, then grew by 19.17% to $93.1 million in 2025.
  • Its last three reported values are $93.1 million in Q3 2025, $91.3 million for Q2 2025, and $83.8 million during Q1 2025.